Neurobiological Technologies (Neurobiological Technologies) Cash Conversion Cycle : 24.11 (As of Sep. 2009)

Neurobiological Technologies Cash Conversion Cycle Chart

Neurobiological Technologies Annual Data
	Trend	Jun00	Jun01	Jun02	Jun03	Jun04	Jun05	Jun06	Jun07	Jun08	Jun09
Cash Conversion Cycle		Get a 7-Day Free Trial					-	46.44	20.65	12.72	5.42

Neurobiological Technologies Quarterly Data
	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09
Cash Conversion Cycle	Get a 7-Day Free Trial															10.02	5.02	6.50	1.16	24.11

Competitive Comparison of Neurobiological Technologies's Cash Conversion Cycle

For the Biotechnology subindustry, Neurobiological Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurobiological Technologies's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurobiological Technologies's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Neurobiological Technologies's Cash Conversion Cycle falls into.

Neurobiological Technologies Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Neurobiological Technologies's Cash Conversion Cycle for the fiscal year that ended in Jun. 2009 is calculated as

Neurobiological Technologies's Cash Conversion Cycle for the quarter that ended in Sep. 2009 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurobiological Technologies  (OTCPK:NTII) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Neurobiological Technologies Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurobiological Technologies (Neurobiological Technologies) Business Description